Deze website is uitsluitend voorbehouden aan beroepsbeoefenaren in Nederland.

Campus
  1. Artikel
  2. Bron: Campus Sanofi
  3. 12 nov 2024
5 min

Global Developments in Early Detection of Autoimmune Type 1 Diabetes

Auteur: Sanofi

Editorial Team

Curious about the characteristics of pre-symptomatic- and stage 3 Type 1 Diabetes? Interested in learning about the potential benefits of screening for autoimmune Type 1 Diabetes? This short film gives you an overview of recent developments in diagnosis of Type 1 Diabetes, showcasing how early detection efforts can benefit those who need it the most.
Hero Banner

Type 1 Diabetes (T1D) is an autoimmune condition which occurs when the immune system accidentally attacks the insulin-producing beta cells in the pancreas.1 The immune system’s attack leads to a progressive decline in beta cell function and leads the body to produce less insulin.2,3

Autoimmune T1D progresses in 3 stages where the first two stages are pre-symptomatic.3,6

The autoimmunity and the progressive decline in functional beta cell mass often begin months to years before the onset of more commonly known symptoms of Type 1 Diabetes.3,6

Autoimmune T1D may present with preventable life-threatening complications, such as diabetic ketoacidosis, which can lead to hospitalization and leave a severe psychological impact.7-11

Early detection of autoimmune T1D may positively affect longevity and decreases morbidity.

Early detection may also have a significant impact on the quality of life and mental health of those who are diagnosed and their families.12-17

Proactive testing for diabetes-specific autoantibodies can transform lives by detecting autoimmune T1D before symptoms develop.18-19

This animation was developed in collaboration with European Diabetes Forum (EUDF), International Diabetes Federation Europe, Federación Española de Diabetes (FEDE), Parliamentarians for Diabetes Global Network and Sanofi.

Neem contact op

Get in touch - dupixent
Wij staan klaar

Heeft u vragen of wilt u meer weten? Wij zorgen dat u zo snel mogelijk geholpen wordt.

Referenties

  1. Diabetes.co.uk: https://www.diabetes.co.uk/body/beta-cells.html (Accessed October 2024)

  2. Powers AC (2021) J Clin Invest. 131(8)e142242

  3. Insel RA et al. (2015) Diabetes Care. 38(10) 1964-1974

  4. DiMeglio LA, et al. (2018) Lancet. 391(10138) - 2449-2462 

  5. Marré ML et al. (2015) Front Cell Dev Biol. 3 67

  6. Phillip et al. (2024) Diabetes Care, 1, 47(8),pp.1276-1298

  7. Nakhla M et al. (2018) CMAJ. 190(14)E416-E421

  8. Cameron FJ et al. (2014). Diabetes Care. 37(6) 1554-1562

  9. Smith LB, et al. Pediatr Diabetes. 2018 19(5) 1025-1033

  10. Kimbell et al. (2021) BMC Pediatrics vol. 21, Article no. 160

  11. Rikos N, et al. (2022) NursRep. 12(3)564-573

  12. Schneider J et al. (2023) Diabetologia. 66(12) pp.2387-2388

  13. Hummel et al. (2023) Diabetologia, Vol. 66, pp. 1633–1642

  14. David MN et al. (2014) Diabetes Care 37(1), pp 9–16

  15. Jeyam A et al. (2021) Diabetes Care 44, pp390–398

  16. Rankin D et al. (2014) Pediatric Diabetes, vol. 15, issue 8, pp543-610 

  17. Nieuwesteeg A et al. (2016) Diabetic Medicine June 2017, vol. 34, issue 6, pp741-867

  18. Narendran P. (2018) Diabetologia. 62(1) 24-27

  19. Raab J et al. (2016) BMJ Open 6-e011144

MAT-BE-2400990–v1.0–OCT/2024  

Gerelateerd